An educational symposium was held from 8-10 August as part of the American Society of Clinical Oncology’s (ASCO) Annual Meeting. In his presentation, Dr Toni Choueiri from Dana-Farber Cancer Institute and Harvard Medical School in Cambridge, USA, discussed treatment for patients with metastatic renal cell carcinoma (RCC) who have previously been treated with immunotherapy.
Currently, immunotherapy or immunotherapy combinations are the standard of care for most patients with metastatic RCC.
Patients who progress on sunitinib and subsequent nivolumab have a number of treatment options, such as a VEGF-TKI (axitinib, cabozantinib), nivolumab plus ipilimumab combination, VEGF-TKI plus immunotherapy combination, a clinical trial of a new drug (e.g. HIF-2 inhibitors or MK-6482) or treatment, or all of the above may be considered.
In summary, there is moderate data supporting VEGF-TKI, combination immunotherapy, and combination immunotherapy with VEGF-TKI in patients who have progressed following initial immunotherapy. New drugs remain welcome to add new therapeutic approaches for these patients.